The Cellular Mechanics of Drug Resistance in Lung Cancer
A recent study published in Cell Death & Disease reveals a novel mechanism by which cancer-associated fibroblasts (CAFs) confer resistance to osimertinib in non-small cell lung cancer (NSCLC). The research identifies that CAFs promote this resistance through METTL1-mediated m7G modification of the NET1 gene. This RNA modification alters cellular signaling pathways, enabling tumor cells to evade the therapeutic effects of targeted tyrosine kinase inhibitors. The findings highlight the critical role of the tumor microenvironment and epitranscriptomic changes in driving therapeutic failure, offering a new potential target for overcoming drug resistance in oncology.
Study Significance: For hepatologists, this research into the tumor microenvironment and RNA modifications is methodologically adjacent and highly relevant to understanding hepatocellular carcinoma (HCC) progression and therapy resistance. The mechanisms of stromal cell interaction and epitranscriptomic regulation explored here are directly applicable to liver cancer biology, where similar pathways influence fibrosis, tumorigenesis, and response to systemic therapies. This work underscores the need to investigate microenvironmental drivers in chronic liver disease to develop novel combination strategies that target both hepatocytes and their supportive stroma.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
